| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-12-14 | OSE Immunotherapeutics (France) | €398,000 | grant | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France | Cancer - Oncology | Grant |
| 2017-12-13 | Myonexus Therapeutics (USA - OH) | $2.5 million | seed financing round | The Jain Foundation (USA) GFB ONLUS (USA) Rev1 Ventures (USA - OH) investors from the LGMD community. | Rare diseases - Genetic diseases - Neuromuscular diseases | Financing round |
| 2017-12-12 | NorthSea Therapeutics (The Netherlands) | € 25 million | series A financing round | Forbion Capital Partners (The Netherlands) BioGeneration Ventures (The Netherlands) Novo Seeds (Denmark) New Science Ventures (USA - NY) | Hepatic diseases - Liver diseases - Inflammatory diseases | Series A financing round |
| 2017-12-12 | bluebird bio (USA - MA) | $600 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-12-11 | Viking Therapeutics (USA - PA) | $14.8 million | private placement | Endocrinological diseases - Metabolic diseases | Private placement | |
| 2017-12-05 | Cell and Gene Therapy Catapult (UK) Oxford MEStar (UK) AK (Suzhou) Biomedical (Chinaà | undisclosed | grant | Innovate UK-Jiangsu Industrial Challenge Programme (UK - China) | Technology - Services | Grant |
| 2017-12-05 | Grifols (Spain) | € 85 million | loan | European Investment Bank (EIB) | Rare diseases - Genetic diseases | Loan |
| 2017-12-04 | Harmonic Pharma (France) | undisclosed | capital increase | Novacap (France) | Technology - Services | Capital increase |
| 2017-11-30 | Chordia Therapeutics (Japan) | ¥1.2 billion ($ 11 million) | series A financing round | Takeda Pharmaceutical (Japan) Kyoto University Innovation Capital (Japan) Mitsubishi UFJ capital (Japan) SMBC venture (Japan) | Cancer - Oncology | Series A financing round |
| 2017-11-29 | Y-mAbs Therapeutics (US - NY) | $80 million | private placement | HBM Healthcare Investments (Switzerland), current shareholders, Sofimac Partners (France) Scopia Capital Management (US - NY) | Cancer - Oncology | Private placement |
| 2017-11-29 | Y-mAbs Therapeutics (USA - NY) | $80 million | private placement | HBM Healthcare Investments (Switzerland) existing investors Sofinnova Ventures (USA) Scopia Capital Management (USA) | Cancer - Oncology | Private placement |
| 2017-11-17 | VBL Therapeutics/Vascular Biogenics (Israel) | financing round | Cancer - Oncology | Financing round | ||
| 2017-11-15 | Erytech Pharma | $130 million | capital increase | Cancer - Oncology - Rare diseases | Capital increase | |
| 2017-11-10 | Transgene (France) | € 14.4 million | capital increase | qualified U.S. and European institutional investors including Institut Mérieux (France) and Dassault Belgique Aviation | Cancer - Oncology - Infectious diseases | Capital increase |
| 2017-11-08 | InflaRX (Germany) | $100 million | IPO | Inflammatory diseases | IPO | |
| 2017-11-06 | Nouscom (Switzerland) | €42 Million | series B financing round | Abingworth (UK) 5AM Ventures (USA - CA) LSP (The Netherlands) Versant Ventures. (USA - CA) | Cancer - Oncology | Series B financing round |
| 2017-11-02 | Mina Therapeutics (UK) LGC LINK (UK) | £400,000 | grant | Innovate UK (UK) | Liver diseases - Hepatic diseases | Grant |
| 2017-11-02 | 20Med Therapeutics (NL) | Twente Technology Fund (TTF) (NL), Oost NL (NL), | Restructuring | |||
| 2017-11-02 | 20Med Therapeutics (NL) | undisclosed | financing round | Twente Technology Fund (TTF) (NL), Oost NL (NL) through regional innovation fund Innovatiefonds Twente (IFT) | Technology - Services | Financing round |
| 2017-10-24 | Immune Design (USA - MA) | $86.6 million | private placement | Cancer - Oncology | Private placement |
